Points to consider in assessing and appraising predictive genetic tests.

Area of Science:

• Genetics
• Health Economics
• Bioethics

Background:

• Predictive genetic testing is increasingly utilized, necessitating robust evidence for decision-making.
• Limited healthcare budgets and specific coverage decisions highlight the need for benefit-harm assessments.
• Current evaluation methods face challenges due to practical and ethical constraints in clinical trials.

Purpose of the Study:

• To provide an overview of considerations for assessing genetic test benefits and harms.
• To explore ethical and economic factors in genetic test appraisal.
• To discuss the exceptionality of genetic tests and the need for tailored assessment methods.

Main Methods:

• Literature review and conceptual analysis.
• Examination of challenges in clinical trial design for genetic tests.
• Discussion of personal utility and broader cost implications.

Main Results:

• Evidence of medical benefits and harms is often limited.
• Clinical endpoints may not fully capture the value of genetic tests.
• Costs of tests and counseling may not reflect total care expenses.

Conclusions:

• Assessing genetic tests requires consideration beyond traditional clinical endpoints.
• Ethical and economic reflections are crucial for appropriate appraisal.
• The unique nature of genetic tests may necessitate novel assessment approaches.